Highlights Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
15.6 ^USD	+1.10%		-2.44%	-27.31%

Apr. 09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
Apr. 03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Denali Therapeutics Files Prospectus for Secondary Offering	Mar. 22	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	Feb. 27	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	Feb. 27	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	Feb. 16	DJ
Sanofi: failure of a phase 2 trial against ALS	Feb. 16	CF
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	Feb. 07	CI
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium	Feb. 01	CI
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	Jan. 08	CI
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q3 Revenue $1.3M	Nov. 07	MT
Denali Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) at SSIEM 2023	23-08-30	CI
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q2 Revenue $294.1M	23-08-08	MT
Denali Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Denali Therapeutics Announces Robust Reduction in Neurofilament Light with DNL310 Treatment in MPS II (Hunter Syndrome)	23-06-20	CI
Denali Therapeutics Inc. and Biogen Inc. Plans to Revisions BIIB122 Clinical Development Program for BIIB122	23-06-05	CI
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q1 Revenue $35.1M	23-05-08	MT
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Biogen Exercises Option to License Denali's Antibody Transport Vehicle Program Targeting Amyloid Beta	23-04-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Highlights

Filters